Postmarket Industry Studies In Sentinel A Future Challenge, Woodcock Says

FDA has not yet sorted out whether or how drug firms could tap into its upcoming Sentinel electronic drug safety surveillance system to conduct postmarket studies required by the agency, Center for Drug Evaluation and Research Director Janet Woodcock said during a public workshop in Washington, D.C. Jan. 11